SCHEMBL7080281

SCHEMBL7080281

CC(=O)OC1=Cc2ccccc2OC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.50
SMN1; SMN2 Q16637 5/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
NFKB1 P19838 2/20 0.45
NFKB2 Q00653 2/20 0.45
RELA Q04206 2/20 0.45
PTGS1 P23219 5/20 0.43
PTGS2 P35354 5/20 0.43
MAOB P27338 4/20 0.42
MAOA P21397 3/20 0.42
ALDH1A1 P00352 5/20 0.42
MAPT P10636 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
KDM4E B2RXH2 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150887 0.85 ALOX5 (0.48) ALOX5SMN1; SMN2NPC1RAB9ANFKB1
SCHEMBL29082480 0.84 ALOX5 (0.48) ALOX5SMN1; SMN2NPC1RAB9ANFKB1
SCHEMBL27351322 0.81 ALOX5 (0.44) ALOX5SMN1; SMN2NPC1RAB9ANFKB1
SCHEMBL18998229 0.77 ALOX5 (0.36) ALOX5SMN1; SMN2ALDH1A1MAPTMTNR1A
SCHEMBL31276994 0.76 SERPINE1 (0.50) ALOX5PTGS1PTGS2MAOBALDH1A1
SCHEMBL4442002 0.75 MAOA (0.45) SMN1; SMN2PTGS1PTGS2MAOBMAOA
SCHEMBL9058393 0.75 ALOX5 (0.67) ALOX5SMN1; SMN2NPC1RAB9ANFKB1
SCHEMBL31114397 0.74 ALOX5 (0.43) ALOX5SMN1; SMN2NPC1RAB9ANFKB1
SCHEMBL30661164 0.73 MEN1 (0.39) SMN1; SMN2PTGS1PTGS2MAOBMAOA
SCHEMBL7034335 0.73 ALOX5 (0.42) ALOX5SMN1; SMN2NPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102596940-B Heterocyclically substituted azolyl benzene fungicides DU PONT 2015-01-28 CN disclosed
CN-102596940-A Heterocyclically substituted azolyl benzene fungicides DU PONT 2012-07-18 CN disclosed
US-20030135045-A1 Glycoprotein IIb/IIIa antagonists FISHER MATTHEW J (US) 2003-07-17 US disclosed
US-20030130342-A1 Glycoprotein llb/llla antagonists FISHER MATTHEW J (US) 2003-07-10 US disclosed
EP-0804431-B9 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2003-01-02 EP disclosed
US-6472405-B1 Glycoprotein IIB/IIIA antagonists ELI LILLY AND COMPANY 2002-10-29 US disclosed
EP-0635492-B1 Glycoprotein IIb/IIIa antagonists LILLY CO ELI (US) 2002-10-02 EP disclosed
US-6448269-B1 SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS ELI LILLY AND COMPANY 2002-09-10 US disclosed
EP-0804431-B1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 2002-07-24 EP disclosed
US-6137002-A USEFUL FOR PREVENTION OF THROMBOSIS; FOR TREATING ATHEROSCLEROSIS AND ARTERIOSCLEROSIS, ACUTE MYOCARDIAL INFARCTION, CHRONIC STABLE ANGINA, UNSTABLE ANGINA, TRANSIENT ISCHEMIC ATTACKS AND STROKES, PERIPHERAL VASCULAR DISEASE, ELI LILLY AND COMPANY (US) 2000-10-24 US disclosed
US-6020362-A ANTICOAGULANTS ELI LILLY AND COMPANY (US) 2000-02-01 US disclosed
EP-0804431-A4 GLYCOPROTEIN IIb/IIIa ANTAGONISTS LILLY CO ELI (US) 1998-04-29 EP disclosed
US-5731324-A Glycoprotein IIb/IIIa antagonists ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
EP-0804431-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1997-11-05 EP disclosed
US-5618843-A INHIBIT PLATELET AGGREGATION ELI LILLY AND COMPANY (US) 1997-04-08 US disclosed
WO-1996022288-A1 GLYCOPROTEIN IIb/IIIa ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-07-25 WO disclosed
EP-0635492-A1 Glycoprotein IIb/IIIa antagonists ELI LILLY AND COMPANY (US) 1995-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135045-A1 Glycoprotein IIb/IIIa antagonists GP6, TBXA2R, ITGA2B ALOX5 1790/4885SMN1; SMN2 4758/4885NPC1 3592/4885
US-20030130342-A1 Glycoprotein llb/llla antagonists SELL, SELPLG, LY96 ALOX5 1175/4885SMN1; SMN2 4854/4885NPC1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.